The combined use of BTYNB (an IGF2BP1 inhibitor), a BRD inhibitor, and YM-155 (a BIRC5 inhibitor) can synergistically inhibit the growth of MNA-NB cells, supporting its therapeutic potential (Hagemann et al., 2023). This evidence concerns the gene BIRC5 and neuroblastoma.